110. ブラウ症候群 Disease details / Clinical trials / Drug dev / DR info /
臨床試験数 : 3 / 薬物数 : 3 - (DrugBank : 1) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 39
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
Janus kinase inhibitor
Peking Union Medical College Hospital
2024 Phase 4 NCT06660329 China
OD-07656
Odyssey Therapeutics
2024 Phase 1 NCT06206811 Australia
Tofacitinib
Tongji Hospital
2017 - NCT06688838 China
Peking Union Medical College Hospital
2024 Phase 4 NCT06660329 China
OD-07656
Odyssey Therapeutics
2024 Phase 1 NCT06206811 Australia
Tofacitinib
Tongji Hospital
2017 - NCT06688838 China